0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The Emboless® venous chamber efficiently reduces air bubbles: a randomized study of chronic hemodialysis patients

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          ABSTRACT

          Background

          When blood passes the extracorporeal circuit, air microbubbles (MBs) contaminate the blood. Some MBs will end up as microemboli in the lung, heart, and brain. MB exposure has no medical purpose and is considered to be bio-incompatible. Selecting venous chambers with a high removal rate of MBs is warranted to reduce the risks of air bio-incompatibility. The primary aim was to compare the Fresenius 5008 (F5008-VC) and the Emboless ® (Emboless-VC) venous chambers regarding the elimination of MBs in the return bloodline during hemodialysis (HD).

          Methods

          Twenty patients underwent 80 sessions of cross-over HD using both the F5008-VC and the Emboless-VC randomized such that half started with the F5008-VC and half with the Emboless-VC. For 32 of the 80 sessions, measurements were also performed during hemodiafiltrations (HDF) after the initial HD. MBs were measured with an ultrasound device (within the size range of 20–500 µm) at the “inlet” and “outlet” bloodline of the venous chambers. The Wilcoxon pairwise test compared the percentage of MB elimination between venous chambers.

          Results

          During HD, the median reduction of MBs for the outlet was 39% with the F5008-VC and 76% with the Emboless-VC ( < .001). During HDF, the reduction was 28% with the F5008-VC and 70% with the Emboless-VC ( < .001).

          Conclusion

          Fewer MBs and subsequently fewer microemboli entered the bloodline of the patient using the Emboless-VC compared to the F5008-VC venous chamber during HD and during HDF. Venous chambers with a high removal rate of MBs will reduce the extent of air emboli.

          Graphical Abstract

          Graphical Abstract

          Related collections

          Most cited references26

          • Record: found
          • Abstract: not found
          • Article: not found

          World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.

          (2013)
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Recovery time, quality of life, and mortality in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

            There is limited information about the clinical and prognostic significance of patient-reported recovery time.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Mortality in chronic kidney disease and renal replacement therapy: a population-based cohort study

              Objective To compare mortality in chronic kidney disease (CKD) stages 4 and 5 (estimated glomerular filtration rate <30 mL/min/1.73 m2), peritoneal dialysis, haemodialysis and transplanted patients. Design Population-based cohort study. Setting Swedish national healthcare system. Participants Swedish adult patients with CKD stages 4 and 5 (n=3040; mean age 66 years), peritoneal dialysis (n=725; 60 years), haemodialysis (n=1791; 62 years) and renal transplantation (n=606; 48 years) were identified in Stockholm County clinical quality registers for renal disease between 1999 and 2010. Five general population controls were matched to each patient by age, sex and index year. Exposure CKD status (stage 4 or 5/peritoneal dialysis/haemodialysis/transplanted). Primary outcome All-cause mortality was ascertained from the Swedish Causes of Death Register. Mortality HRs were estimated using Cox regression conditioned on age, sex, diabetes status, education level and index year. Results During 6553 person-years, 766 patients with CKD stages 4 and 5 died (deaths/100 person-years 12, 95% CI 11 to 13) compared with 186 deaths during 1113 person-years in peritoneal dialysis (17, 95% CI 15 to 19), 924 deaths during 3680 person-years in haemodialysis (25, 95% CI 23 to 27) and 53 deaths during 2935 person-years in transplanted patients (1.8, 95% CI 1.4 to 2.4). Against matched general population controls, the mortality HR was 3.6 (95% CI 3.2 to 4.0) for CKD, 5.6 (95% CI 3.5 to 8.9) for transplanted patients, 9.2 (95% CI 6.6 to 12.7) for peritoneal dialysis and 12.6 (95% CI 10.8 to 14.6) for haemodialysis. In direct comparison versus CKD, the mortality HR was 1.7 (95% CI 1.4 to 2.1) for peritoneal dialysis, 2.6 (95% CI 2.3 to 2.9) for haemodialysis and 0.5 (95% CI 0.3 to 0.7) for transplanted patients. Conclusions We did not find support for mortality in CKD to be similar to dialysis mortality. The patients with CKD stages 4 and 5 had considerably lower mortality risk than dialysis patients, and considerably higher risk than transplanted patients and matched general population controls.
                Bookmark

                Author and article information

                Contributors
                Journal
                Clin Kidney J
                Clin Kidney J
                ckj
                Clinical Kidney Journal
                Oxford University Press
                2048-8505
                2048-8513
                November 2024
                24 October 2024
                24 October 2024
                : 17
                : 11
                : sfae323
                Affiliations
                Department of Public Health and Clinical Medicine, the Skelleftea Unit, Umea University , Umea, Sweden
                Department of Public Health and Clinical Medicine, Unit of Medicine, Umea University , Umea, Sweden
                Department of Public Health and Clinical Medicine, Unit of Medicine, Umea University , Umea, Sweden
                Author notes
                Correspondence to: Bernd Stegmayr; E-mail: bernd.stegmayr@ 123456umu.se
                Author information
                https://orcid.org/0000-0003-2694-7035
                Article
                sfae323
                10.1093/ckj/sfae323
                11579606
                39574541
                ecf7c807-19ed-43c0-b15d-c2687f3af6c7
                © The Author(s) 2024. Published by Oxford University Press on behalf of the ERA.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 03 June 2024
                : 21 November 2024
                Page count
                Pages: 10
                Funding
                Funded by: Sweden's innovation agency Vinnova, MedTech4Health, Region Västerbotten;
                Categories
                Original Article
                AcademicSubjects/MED00340

                Nephrology
                bio-compatibility,cardiovascular,hemodiafiltration,hemodialysis,thrombosis
                Nephrology
                bio-compatibility, cardiovascular, hemodiafiltration, hemodialysis, thrombosis

                Comments

                Comment on this article